» Articles » PMID: 38560025

Age-related Increase in the Expression of 11β-hydroxysteroid Dehydrogenase Type 1 in the Hippocampus of Male Rhesus Macaques

Overview
Specialty Geriatrics
Date 2024 Apr 1
PMID 38560025
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The hippocampus is especially susceptible to age-associated neuronal pathologies, and there is concern that the age-associated rise in cortisol secretion from the adrenal gland may contribute to their etiology. Furthermore, because 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) catalyzes the reduction of cortisone to the active hormone cortisol, it is plausible that an increase in the expression of this enzyme enhances the deleterious impact of cortisol in the hippocampus and contributes to the neuronal pathologies that underlie cognitive decline in the elderly.

Methods: Rhesus macaques were used as a translational animal model of human aging, to examine age-related changes in gene and protein expressions of (/HSD11B1) in the hippocampus, a region of the brain that plays a crucial role in learning and memory.

Results: Older animals showed significantly ( < 0.01) higher base-line cortisol levels in the circulation. In addition, they showed significantly ( < 0.05) higher hippocampal expression of but not and (i.e., two receptor-encoding genes through which cortisol exerts its physiological actions). A similar age-related significant ( < 0.05) increase in the expression of the HSD11B1 was revealed at the protein level by western blot analysis.

Discussion: The data suggest that an age-related increase in the expression of hippocampal is likely to raise cortisol concentrations in this cognitive brain area, and thereby contribute to the etiology of neuropathologies that ultimately lead to neuronal loss and dementia. Targeting this enzyme pharmacologically may help to reduce the negative impact of elevated cortisol concentrations within glucocorticoid-sensitive brain areas and thereby afford neuronal protection.

Citing Articles

Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease.

Rolan P, Seckl J, Taylor J, Harrison J, Maruff P, Woodward M Clin Pharmacol Drug Dev. 2025; 14(2):105-115.

PMID: 39748632 PMC: 11788964. DOI: 10.1002/cpdd.1496.

References
1.
Staab C, Maser E . 11beta-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation. J Steroid Biochem Mol Biol. 2010; 119(1-2):56-72. DOI: 10.1016/j.jsbmb.2009.12.013. View

2.
Tomlinson J, Walker E, Bujalska I, Draper N, Lavery G, Cooper M . 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev. 2004; 25(5):831-66. DOI: 10.1210/er.2003-0031. View

3.
Hibberd C, Yau J, Seckl J . Glucocorticoids and the ageing hippocampus. J Anat. 2001; 197 Pt 4:553-62. PMC: 1468170. DOI: 10.1046/j.1469-7580.2000.19740553.x. View

4.
Holmes M, Yau J, Kotelevtsev Y, Mullins J, Seckl J . 11 Beta-hydroxysteroid dehydrogenases in the brain: two enzymes two roles. Ann N Y Acad Sci. 2004; 1007:357-66. DOI: 10.1196/annals.1286.035. View

5.
Uno H . The incidence of senile plaques and multiple infarction in aged macaque brain. Neurobiol Aging. 1993; 14(6):673-4. DOI: 10.1016/0197-4580(93)90067-l. View